The acute effect of tropisetron on ECG parameters in cancer patients

Abstract

In this study, tropisetron did not show any ventricular and atrial arrhythmogenic effect because of repolarization abnormalities. Only it may cause a slight decrease in heart rate.

Electrocardiographic findings of palonosetron in cancer patients

“…In two studies conducted on oral dolasetron, PR, QTc, and QRS prolongations were detected [21,22]. Yavas et al, in their study on tropisetron (5 mg), another 5-HT 3 antagonist, showed sinusal bradycardia at the 30th minute [17]. Most of these studies used anthracycline or its derivatives.…”

“…The adverse effects of 5-HT 3 antagonists such as dolasetron, ondansetron, granisetron, and tropisetron were studied by several authors [2,9,10,17]. Several studies were conducted on healthy individuals on this subject.…”

Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas

“…Accurate testing for Her2 aims to ensure that every patient who might benefit from trastuzumab receives appropriate treatment, and that costly and potentially cardiotoxic trastuzumab40 – 42 is not given to patients with non-overexpressing tumours. Inconsistencies in the sensitivity of IHC Her2 testing have been attributed to the use of different antibodies, differences in tissue fixation and IHC reagents, antigen retrieval methods and interobserver variability 3 43 44…”

Concomitant drugs with low risks of drug–drug interactions for use in oncology clinical trials

“…However, several trials suggested tropisetron and granisetron had few, if not any, side effects on QT interval [54,56]. Palonosetron has recently become available commercially and the QT prolongation risk has not been recorded by the Arizona CERT.…”

“…In regards to the risk of QT interval prolongation, serotonin-receptor antagonists have also been shown to block human potassium and sodium channels, thereby causing potential QT interval prolongation [56]. However, several trials suggested tropisetron and granisetron had few, if not any, side effects on QT interval [54,56].…”